Equities

Aytu Biopharma Inc

Aytu Biopharma Inc

Actions
  • Price (EUR)2.22
  • Today's Change0.00 / 0.00%
  • Shares traded39.00
  • 1 Year change+44.16%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Jun 30 2023202320222021
ASSETS
Cash And Short Term Investments231950
Total Receivables, Net292228
Total Inventory121116
Prepaid expenses8.057.389.78
Other current assets, total0.870.631.29
Total current assets7360105
Property, plant & equipment, net3.876.308.70
Goodwill, net--066
Intangibles, net597185
Long term investments------
Note receivable - long term------
Other long term assets0.790.770.47
Total assets136138266
LIABILITIES
Accounts payable131119
Accrued expenses373649
Notes payable/short-term debt1.563.817.93
Current portion long-term debt/capital leases0.090.1017
Other current liabilities, total5.834.137.41
Total current liabilities6964109
Total long term debt15140.18
Total debt161825
Deferred income tax------
Minority interest------
Other liabilities, total131318
Total liabilities9792128
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital343335316
Retained earnings (accumulated deficit)(304)(288)(178)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity3946138
Total liabilities & shareholders' equity136138266
Total common shares outstanding5.521.931.37
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.